ArticleWorld journal of gastroenterology2026
Beyond monotherapy by acid suppression: Reshaping the management of refractory gastroesophageal reflux disease.
Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is highly prevalent worldwide. Although standard proton pump inhibitor (PPI) or potassium-competitive acid blocker therapy is effective in most patients, some patients develop refractory GERD (rGERD). Previous studies exploring the characteristics and risk factors for rGERD had substantial limitations. A recent multicenter cross-sectional study conducted across 18 medical centers in Shanghai directly compared GERD and rGERD, and identified prolonged disease duration and anxiety as independent high-risk factors for rGERD. Moderate-intensity physical activity for at least 90 minutes/week was found to be a protective factor. The 8-week PPI/potassium-competitive acid blocker therapy is the standard regimen for GERD, whereas adjustments are needed for rGERD, such as switching or increasing the dose of PPIs or using vonoprazan instead. Additionally, endoscopic interventions and surgeries are supplementary options for patients with rGERD. Anti-anxiety interventions, standardized exercise prescriptions, and lifestyle factors such as sleep and weight management should be explored as a "multidimensional risk-targeted intervention" for the management and treatment of rGERD. This multicenter cross-sectional study offers forward-looking findings for rGERD prevention, but has limitations: A single-region sample lacks representativeness, and its cross-sectional design requires long-term randomized controlled trial for causal evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.